Table 1. Incidence proportion and incidence rate of irAEs in patients treated with atezolizumab (alone or in combination) and chemotherapy.

irAE	IO/C-IO(N=6,229)		Chemotherapy(N=3,292)
	irAEn (%)	irAE per100 patient-years	irAEn (%)	irAE per100 patient-years
Any irAE	2707 (43.5)	86.86	823 (25)	66.84
Skin	1476 (23.7)	36.37	475 (14.4)	34.57
Hepatitis	839 (13.5)	17.16	296 (9)	19.66
Thyroid	767 (12.3)	16.14	91 (2.8)	5.79
Pneumonitis	256 (4.1)	4.77	36 (1.1)	2.23
Colitis	93 (1.5)	1.7	9 (0.3)	0.56
Adrenal insufficiency	53 (0.9)	0.97	6 (0.2)	0.37
Pancreatitis	52 (0.8)	0.95	6 (0.2)	0.37
Diabetes mellitus	35 (0.6)	0.64	11 (0.3)	0.68
Myositis myositis+rhabdomyolysis	30 (0.5)	0.55	4 (0.1)	0.25
Meningoencephalitis	29 (0.5)	0.53	4 (0.1)	0.25
Meningitis	23 (0.4)	0.42	4 (0.1)	0.25
Nephritis	20 (0.3)	0.36	3 (0.1)	0.18
Ocular inflammatory toxicity	20 (0.3)	0.36	1 (0)	0.06
Vasculitis	17 (0.3)	0.31	3 (0.1)	0.18
Hypophysitis	12 (0.2)	0.22	0 (0)	0
Systemic immune activation	8 (0.1)	0.15	0 (0)	0
Autoimmune hemolytic anemia	7 (0.1)	0.13	1 (0)	0.06
Guillain-Barre syndrome	6 (0.1)	0.11	0 (0)	0
Encephalitis	6 (0.1)	0.11	0 (0)	0
Myocarditis	4 (0.1)	0.07	1 (0)	0.06
Myasthenia gravis	0 (0)	0	1 (0)	0.06

Any irAE=any of the other immune-related AEs in the table.

Skin=immune-related rash, immune-related severe cutaneous reactions.

Hepatitis=immune-related hepatitis (clinical diagnosis), immune-related hepatitis (laboratory abnormalities).

Thyroid=immune-related hypothyroidism, immune-related hyperthyroidism, immune-related thyroiditis.

irAEs=immune-related adverse events were reported in all study arms, including standard of care without atezolizumab, given the blinded nature of the controlled trials.

irAE n (%) = number and percentage of listed irAE

C-IO, atezolizumab in combination with chemotherapy or bevacizumabIO, atezolizumab monotherapy; irAEimmune-related adverse event